Multiple Sclerosis Treatment Market Forecast 2026: Market Size, Competitive Landscape And Growth Drivers
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Multiple Sclerosis Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The multiple sclerosis treatment market size has seen substantial expansion in recent years. This market is projected to increase from $26.13 billion in 2025 to $27.44 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.0%. The growth observed in prior periods can be attributed to advancements in autoimmune disease research, the availability of injectable MS therapies, the expansion of neurology clinics, the provision of hospital-based treatment, and the ongoing development of biologics.
The multiple sclerosis treatment market is projected to experience consistent expansion in the coming years. It is anticipated to reach $33.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. This projected increase during the forecast period stems from factors such as the adoption of oral therapies, the availability of home-based MS care, improved long-term disease management strategies, innovations in advanced imaging diagnostics, and the development of personalized immunotherapy. Key developments expected during this timeframe encompass the wider availability of disease-modifying therapies, an uptick in oral MS medications, a greater emphasis on early diagnosis, the increasing application of monoclonal antibodies, and the implementation of personalized treatment methods.
Get A Free Sample Report With In-Depth Market Insights:
Multiple Sclerosis Treatment Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing occurrence of neurological disorders is anticipated to boost the multiple sclerosis treatment market in the future. These medical conditions impact the brain, spinal cord, and nerves throughout the body, leading to issues with movement, communication, behavior, or other bodily functions. The uptick in neurological disorders is primarily linked to an aging global populace, as extended lifespans elevate the risk of age-related ailments such as Alzheimer’s. Multiple sclerosis treatment assists in managing these conditions by focusing on the immune system to lessen inflammation, avert nerve damage, and ease symptoms, thereby enhancing patients’ quality of life. For instance, in October 2023, according to the World Federation of Neurology, a UK-based association, more than 40% of the world’s population currently experiences some form of neurological condition, with this burden projected to almost double by 2050. Consequently, the rising incidence of neurological disorders is fueling the expansion of the multiple sclerosis treatment market.
Multiple Sclerosis Treatment Market Segment Performance And Emerging Opportunities
The multiple sclerosis treatment market covered in this report is segmented –
1) By Treatment Type: Immunomodulators, Corticosteroids, Symptomatic Treatments, Monoclonal Antibodies, Oral Therapies
2) By DiseaseType: Clinically Isolated Syndrome, Relapse-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
3) By Route Of Administration: Oral, Injectable, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Immunomodulators: Interferon Beta-1A, Interferon Beta-1B, Glatiramer Acetate
2) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone
3) By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs
4) By Monoclonal Antibodies: Natalizumab, Ocrelizumab, Alemtuzumab, Ofatumumab
5) By Oral Therapies: Fingolimod, Dimethyl Fumarate, Teriflunomide, Cladribine, Siponimod
#Multiple Sclerosis Treatment Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the multiple sclerosis treatment market are creating sophisticated products, such as monoclonal antibody drugs, to improve treatment effectiveness and patient results. Monoclonal antibody drugs are laboratory-produced molecules specifically designed to target particular antigens, and in multiple sclerosis, they function by reducing inflammation and hindering immune cells from assaulting nerve fibers, thereby controlling the disease’s development. For example, in February 2024, Roche Pharma India, a pharmaceutical company located in India, unveiled Ocrevus (Ocrelizumab) for the management of multiple sclerosis (MS). This drug specifically targets CD20-positive B cells, helping to lessen inflammation and nerve damage in MS. It represents the first approved treatment for both relapsing and primary progressive forms of MS, considerably reducing relapse rates and slowing the advancement of disability with the convenience of twice-yearly infusions.
Multiple Sclerosis Treatment Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the multiple sclerosis treatment market are Biogen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi Genzyme, Merck KGaA, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson (Janssen), TG Therapeutics Inc., Acorda Therapeutics Inc., Takeda Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Almirall S.A., Otsuka Pharmaceutical Co. Ltd., Apitope International NV, BrainStorm Cell Therapeutics Inc., Roche Diagnostics, InnoCare Pharma, NervGen Pharma Corp., Receptos Inc., Biogen Idec International GmbH, MedDay Pharmaceuticals SA, Genentech Inc., Roche Holding AG
View The Full Multiple Sclerosis Treatment Market Report:
Multiple Sclerosis Treatment Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the multiple sclerosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
